Results 111 to 120 of about 4,315,874 (223)

Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia

The Journal of Clinical Pharmacology, Volume 66, Issue 10, October 2026.
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Albert Qin, Lucia Masarova, Haoqi Chen, Zhijian Xiao, Jie Jin, Harinder Gill, Brandi N Reeves, Firas El Chaer, Keita Kirito, Norio Komatsu, Ghaith Abu‐Zeinah, Kazuya Shimoda, Oleh Zagrijtschuk, Toshiaki Sato, Daoxiang Wu, Lei Wu, Xia Su, Yucheng Gao, Jie Cui, Lei Zhang, Ruben A Mesa   +20 more
wiley   +1 more source

Coexistence of primary myelofibrosis and chronic lymphocytic leukemia

Blood and Lymphatic Cancer: Targets and Therapy, 2014
Sonja Burgstaller, Josef Thaler Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV, Wels, AustriaAbstract: Coexistence of two hematologic malignancies in one patient is generally a rare phenomenon.
Burgstaller S, Thaler J
doaj  

Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Background TP53 mutations (TP53m) are uncommon in chronic‐phase Ph–negative myeloproliferative neoplasms but become enriched in myelofibrosis (MF) and accelerated/blast phase myeloproliferative (AP/BP‐MPN). Their prevalence, allelic distribution, and phase‐stratified outcomes have not been systematically synthesized.
Mahmood Aldapt, Rasha Kaddoura, Ahmed O. Saleh, Mostafa Najim, Ahmad Salem, Abdulrahman F. Al‐Mashdali, Bassam Muthanna, Ruba Adel Aweer, Marrita Rabadi, Shehab F. Mohamed   +9 more
wiley   +1 more source

What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog

Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson, King Long Hannah Lee, Megan Dietz, Sarah Guess, Laura White, Mara S. Varvil   +5 more
wiley   +1 more source

When Liver Disease Misleads the Diagnosis: Two Cases of TAFRO Syndrome With Porto‐Sinusoidal Vascular Disease

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Background TAFRO syndrome is a rare inflammatory disorder whose hepatic manifestations may mimic decompensated cirrhosis. Cases: We report two women with TAFRO syndrome associated with portal‐sinusoidal vascular disorder (PSVD), a rare cause of non‐cirrhotic portal hypertension. In both cases, liver biopsy excluded cirrhosis and confirmed PSVD.
Laura Dassy, Fanny Poletti, Kaoutar Hafraoui, Marie Lejeune, Joan Somja, Patrick Collins, Julien Guiot, Ivan Theate, Jo Caers, Jean Delwaide, Astrid Marot, Virginie Putzeys, Gaëlle Vertenoeil   +12 more
wiley   +1 more source

Fumarate and Its Esters: Physiology, Pathology, Molecular Mechanisms, Diseases, and Therapy

MedComm, Volume 7, Issue 10, October 2026.
Fumarate is an endogenous immunometabolite that regulates metabolism, redox homeostasis, and inflammation. Although fumaric acid esters (FAEs) share several molecular targets with fumarate, their distinct physicochemical properties confer unique biological activities and therapeutic applications.
Peng Zhu, Mengling You, Yi Zeng, Jinglin Zhang, Si Chen, Rong Rong, Xiaobo Xia   +6 more
wiley   +1 more source

Survival of patients with primary myelofibrosis.

, 2013
Patients were categorized according they were diagnosed with prefibrotic myelofibrosis, myelofibrosis-fibrotic type with early bone marrow fibrosis (grade 1) or myelofibrosis-fibrotic type with advanced bone marrow fibrosis (grade 2 or 3).
Paolo Catarsi (325689), Giovanni Barosi (325686), Adriana Carolei (325688), Vittorio Rosti (133339), Antonina M. Isgrò (325690), Margherita Massa (133323), Valentina Poletto (325692), Rita Campanelli (325687), Gianluca Viarengo (325693), Laura Villani (10719), Umberto Magrini (325155), Elisa Bonetti (133296), Letizia Lupo (325691)   +12 more
core   +1 more source

CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms

Annals of Hematology
Polycythemia vera (PV) and Essential thrombcythemia (ET) are myeloproliferative neoplasms (MPNs) that can progress to secondary myelofibrosis, a complication associated with increased mortality. Circulating CD34-positive cells at diagnosis can be used to
Marine Demoy, Maxence Bauvais, Agathe Vely, Thomas Nicol, Jérémie Riou, Hortense Le Jeanne, Aurélien Bauduin, Hubert Rambaud, Françoise Boyer, Franck Geneviève, Agathe Boussaroque, Marie-Christine Copin, Valérie Ugo, Corentin Orvain, Damien Luque Paz   +14 more
doaj   +1 more source

The Etiology and Diagnosis of Primary Myelofibrosis: Case Study

, 2022
Primary myelofibrosis is a myeloproliferative neoplasm. It is the rarest among the group of myeloproliferative neoplasms and the incidence is 0.1-1 per 1,00,000 per year.
Khan, Saima, Sharma, Brijesh, Jyotsana, P. Lalita, Indu, M. B.   +3 more
core  

The thrombopoietin receptor S264F mutant drives MPN with marrow fibrosis through a dual mechanism

HemaSphere, Volume 10, Issue 10, October 2026.
Charlotte Lees, Emile Brandt, Emmanuel Dutranoix, Gabriel Levy, Bogdan I. Iorga, Hosuk Ryou, Jens Rittscher, Daniel Royston, Stefan N. Constantinescu, Adam J. Mead   +9 more
wiley   +1 more source